Omega cuts 35% of work­force; Rhythm, Cer­voMed, Sur­rozen raise new fund­ing

Plus: Treve­na’s strate­gic re­view for its com­mer­cial drug, Al­ger­non’s new fo­cus and An­tibe Ther­a­peu­tics’ clin­i­cal hold.

Omega Ther­a­peu­tics cuts 35% of work­force: The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER